Pilot/Exploratory Studies Core

试点/探索性研究核心

基本信息

  • 批准号:
    10201469
  • 负责人:
  • 金额:
    $ 16.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-06-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Pilot / Exploratory Studies Core (PESC): Project Summary The overall goal of the Pilot / Exploratory Studies Core (PESC) is to cultivate and support cutting edge pilot and exploratory studies that will advance the development of effective prevention and/or therapies for frailty and hence facilitate independence in older adults. The PESC Core leader, in close collaboration with other core leaders, set scientific goals for the next stages of frailty research, and then work to identify investigators whose expertise and career goals would be applicable to furthering our knowledge in the targeted areas. These leaders search for pilot and exploratory studies that can collect data required in order to select or design the future large-scale or confirmatory studies needed to establish frailty mechanisms, determine etiologies, or develop novel treatment and screening approaches. Studies selected for funding in the first year of this cycle include a study that pilots a behavioral intervention to concurrently address pain and frailty in older African American women, a metabolomic study that seeks to identify frailty-related metabolite signatures of energy dysregulation through a C 13 labeled glucose tolerance test, and study that seeks to further understanding of the connection between sleep disturbance and frailty by identifying specific polysomnographic signatures implicated, using functional data analysis, and exploring a potential cyclical relationship. The specific aims of the PESC are to 1) advance the science and translation of frailty research by providing intellectual leadership necessary to identify targeted areas of research and investigators that can best accomplish the translational goals of this OAIC, 2) to support the development of well-designed and informative pilot studies, 3) to provide and conduct longitudinal mentorship to supported investigators through completion of the pilot award and pursuit of funding for the next stage of research, 4) to further guide the translation of any pilot study results, and 5) to expand the research environment and network of frailty-focused investigators needed to accomplish the overall OAIC goals. These aims will be carried out in close collaboration with biostatistics, biological mechanisms, and clinical translational and recruitment core leaders to ensure optimal design and access to core resources needed for study success. Important findings from this core can be broadly disseminated through the new Information Dissemination Core (IDC) proposed in this application. This core will guide the translation of pilot work into a deeper understanding of the basic biology and population implications of frailty and into interventions that will prevent or treat frailty hence help maintain independence.
试点/探索性研究核心(PESC):项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NEAL S FEDARKO其他文献

NEAL S FEDARKO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NEAL S FEDARKO', 18)}}的其他基金

Multiplexed enzyme-linked immunosorbent assay workstation for clinical research
用于临床研究的多重酶联免疫吸附测定工作站
  • 批准号:
    10413539
  • 财政年份:
    2022
  • 资助金额:
    $ 16.6万
  • 项目类别:
Autoantibodies, Frailty and Cognitive Decline
自身抗体、虚弱和认知能力下降
  • 批准号:
    9371387
  • 财政年份:
    2017
  • 资助金额:
    $ 16.6万
  • 项目类别:
Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate Cancer
小整合素结合糖磷蛋白作为前列腺癌的生物标志物
  • 批准号:
    8277907
  • 财政年份:
    2011
  • 资助金额:
    $ 16.6万
  • 项目类别:
Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate Cancer
小整合素结合糖磷蛋白作为前列腺癌的生物标志物
  • 批准号:
    8474712
  • 财政年份:
    2011
  • 资助金额:
    $ 16.6万
  • 项目类别:
Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate Cancer
小整合素结合糖磷蛋白作为前列腺癌的生物标志物
  • 批准号:
    8108168
  • 财政年份:
    2011
  • 资助金额:
    $ 16.6万
  • 项目类别:
FASEB Summer Research Conference on Osteopontin Biology
FASEB 骨桥蛋白生物学夏季研究会议
  • 批准号:
    8004256
  • 财政年份:
    2010
  • 资助金额:
    $ 16.6万
  • 项目类别:
2007 Small Intergin Binding Proteins Gordon Research Conference
2007 年小整合素结合蛋白戈登研究会议
  • 批准号:
    7329283
  • 财政年份:
    2007
  • 资助金额:
    $ 16.6万
  • 项目类别:
Small integrin-binding proteins and tumor progression
小整合素结合蛋白与肿瘤进展
  • 批准号:
    7147389
  • 财政年份:
    2006
  • 资助金额:
    $ 16.6万
  • 项目类别:
Small integrin-binding proteins and tumor progression
小整合素结合蛋白与肿瘤进展
  • 批准号:
    7425047
  • 财政年份:
    2006
  • 资助金额:
    $ 16.6万
  • 项目类别:
Small integrin-binding proteins and tumor progression
小整合素结合蛋白与肿瘤进展
  • 批准号:
    7259482
  • 财政年份:
    2006
  • 资助金额:
    $ 16.6万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 16.6万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 16.6万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 16.6万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 16.6万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 16.6万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 16.6万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 16.6万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 16.6万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 16.6万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 16.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了